Palbociclib works by inhibiting CDK4/6, which are enzymes crucial for cell cycle progression from the G1 phase to the S phase. By blocking these enzymes, palbociclib halts the cell cycle, preventing cancer cells from multiplying. This makes it particularly effective in hormone receptor-positive, HER2-negative breast cancer.
